**Version 2007.7** 

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC<br>DRUG CLASS                          | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS   | PA<br>CRITERIA   |
|--|---|---|--|
| ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS | LOTREL (benazepril/amlodipine) TARKA (trandolapril/verapamil) | amlodipine/benazepril LEXXEL (enalapril/felodipine)             | Each of the preferred agents must be tried for at least two weeks each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.   |
| Effective 4/2/07                                   |   |   | Patients starting therapy in this class must show a documented allergy to the preferred agents before a non-preferred agent will be authorized.  |
| ACNE AGENTS, TOPICAL                               | AN  | TIBIOTICS   | A trial of 30 days of one of the preferred agents in each category   |
| Effective 4/2/07                                   | AKNE-MYCIN (erythromycin) clindamycin                         | CLINDAGEL (clindamycin) CLINDAREACH (clindamycin) <sup>NR</sup> | will be required before a non-preferred agent will be authorized. (In cases of pregnancy, a trial of retinoids will not be required.) PA required after 17 years of age for tretinoin products.  |
|  | erythromycin  | EVOCLIN (clindamycin)   | - Control of the cont |
|  |   | TINOIDS   | <del>-</del>   |
|  | RETIN-A MICRO (tretinoin) <sup>CL</sup>                       | DIFFERIN (adapalene)  |  |
|  | TAZORAC (tazarotene) tretinoin <sup>CL</sup>                  |   |  |
|  |   | ATUEDO  |  |
|  | OTHERS  |   | 4  |
|  | AZELEX (azelaic acid) BENZACLIN                               | BENZAMYCIN PAK (benzoyl peroxide/erythromycin)                  |  |
|  | (benzoyl peroxide/clindamycin)                                | BENZIQ (benzoyl peroxide)                                       |  |
|  | benzoyl peroxide  | BREVOXYL (benzoyl peroxide)                                     |  |
|  | CLINAC BPO (benzoyl peroxide)                                 | erythromycin/benzoyl peroxide                                   |  |
|  | DUAC (benzoyl peroxide/ clindamycin)                          | INOVA (benzoyl peroxide)  |  |
|  | sodium sulfacetamide  | INOVA 4/1   |  |
|  |   | (benzoyl peroxide/ salicylic acid)                              |  |
|  |   | KLARON (sodium sulfacetamide)                                   |  |
|  |   | LAVOCLEN (benzoyl peroxide) <sup>NR</sup>                       |  |
|  |   | NEOBENZ MICRO (benzoyl peroxide)                                |  |
|  |   | NUOX (benzoyl peroxide/sulfur)                                  |  |
|  |   | SULFOXYL (benzoyl peroxide/sulfur)                              |  |
|  |   | TRIAZ (benzoyl peroxide)  |  |
|  |   | ZACLIR (benzoyl peroxide)                                       |  |
|  |   | ZIANA (clindaymcyin/tretinoin) <sup>NR</sup>                    |  |
|  |   | ZODERM (benzoyl peroxide)                                       |  |

#### **Version 2007.7**

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC<br>DRUG CLASS | PREFERRED<br>AGENTS       | NON-PREFERRED<br>AGENTS   | PA<br>CRITERIA   |
|---------------------------|---------------------------|---------------------------|--|
| ALZHEIMER'S AGENTS        | CHOLINESTERASE INHIBITORS |                           | A trial of a preferred agent will be required before a non-preferred |
|                           | ARICEPT (donepezil)       | COGNEX (tacrine)          | agent In this class will be authorized.                              |
| Effective 10/01/07        | ARICEPT ODT(donepezil)    | RAZADYNE (galantamine)    | Currrent prescriptions for Razadyne and Razadyne ER will be          |
|                           | EXELON (rivastigmine)     | RAZADYNE ER (galantamine) | grandfathered.   |
|                           | NMDA RECEPT               | OR ANTAGONIST             |  |
|                           | NAMENDA (memantine)       |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |
|                           |                           |                           |  |

**Version 2007.7** 

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

|                        |                               | VCISION 2007:1                       | Originally i Osted: 3/13/0   |
|------------------------|-------------------------------|--------------------------------------|--|
| THERAPEUTIC            | PREFERRED                     | NON-PREFERRED                        | PA   |
| DRUG CLASS             | AGENTS                        | AGENTS                               | CRITERIA   |
| ANALGESICS, NARCOTIC - | APAP/codeine                  | ACTIQ (fentanyl)                     | Three of the preferred agents must be tried for at least 72 hours  |
| SHORT ACTING           | ASA/codeine                   | butalbital/APAP/caffeine/codeine     | before a non-preferred agent will be authorized unless one of the  |
| (Non-parenteral)       | codeine                       | butalbital/ASA/caffeine/codeine      | exceptions on the PA form is present.  |
|                        | dihydrocodeine/ APAP/caffeine | COMBUNOX (oxycodone/ibuprofen)       |  |
| Effective 4/2/07       | hydrocodone/APAP              | DARVOCET (propoxyphene/APAP)         | Fentanyl lozenges will only be approved as an adjunct to a long-<br>acting agent. Fentanyl lozenges will not be approved for |
|                        | hydrocodone/ibuprofen         | DARVON (propoxyphene)                | monotherapy.   |
|                        | hydromorphone                 | DEMEROL (meperidine)                 | monotropy.   |
|                        | levorphanol                   | DILAUDID (hydromorphone)             | Limits: Quantities exceeding 240 tablets per 30 days (8  |
|                        | morphine                      | fentanyl                             | tablets/day) for agents containing 500 mg of acetaminophen will  |
|                        | oxycodone                     | FENTORA (fentanyl) <sup>NR</sup>     | require a prior authorization and review by the Medical Director.  |
|                        | oxycodone/APAP                | FIORICET W/ CODEINE                  |  |
|                        | oxycodone/ASA                 | (butalbital/APAP/caffeine/codeine)   |  |
|                        | pentazocine/APAP              | FIORINAL W/ CODEINE                  |  |
|                        | pentazocine/naloxone          | (butalbital/ASA/caffeine/codeine)    |  |
|                        | propoxyphene/APAP             | LORCET, LORTAB (hydrocodone/APAP)    |  |
|                        | tramadol                      | LYNOX (oxycodone/APAP) <sup>NR</sup> |  |
|                        | tramadol/APAP                 | meperidine                           |  |
|                        |                               | OPANA (oxymorphone)                  |  |
|                        |                               | OXYFAST, OXYIR (oxycodone)           |  |
|                        |                               | PANLOR                               |  |
|                        |                               | (dihydrocodeine/ APAP/caffeine)      |  |
|                        |                               | PERCORAN (overedone/APAP)            |  |
|                        |                               | PERCODAN (oxycodone/ASA)             |  |
|                        |                               | propoxyphene                         |  |
|                        |                               | TALACEN (pentazocine/APAP)           |  |
|                        |                               | TALWIN NX (pentazocine/naloxone)     |  |
|                        |                               | TYLENOL W/CODEINE (APAP/codeine)     |  |
|                        |                               | ULTRACET (tramadol/APAP)             |  |
|                        |                               | ULTRAM (tramadol)                    |  |
|                        |                               | VICODIN (hydrocodone/APAP)           |  |
|                        |                               | VICOPROFEN (hydrocodone/ibuprofen)   |  |

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.  $^{\text{CL}}$  - Requires Clinical PA  $^{\text{NR}}$  – New drug has not been reviewed by P & T Committee

#### **Version 2007.7**

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC                           | PREFERRED  | NON-PREFERRED   | PA  |
|---------------------------------------|--|---|---|
| DRUG CLASS                            | AGENTS   | AGENTS  | CRITERIA  |
| ANALGESICS, NARCOTIC - LONG ACTING    | DURAGESIC (fentanyl)<br>KADIAN (morphine)  | AVINZA (morphine)<br>fentanyl   | Three preferred narcotic analgesics, including at least one long-<br>acting agent, must be tried for at least 72 hours before a non-<br>preferred agent will be authorized unless one of the exceptions |
| (Non-parenteral)                      | methadone<br>morphine ER   | MS CONTIN (morphine) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER             | on the PA form is present.  Exception: Oxycodone ER will be authorized if a diagnosis of  |
|                                       |  | OXYCONTIN (oxycodone) ULTRAM ER (tramadol)  | cancer is submitted without a trial of the preferred agents.  |
| ANDROGENIC AGENTS  Effective 10/01/07 | ANDRODERM (testosterone) ANDROGEL (testosterone)   | TESTIM (testosterone)   | The non-preferred agents will be approved only if one of the exceptions on the PA form is present.  |
| ANGIOTENSIN II RECEPTOR               | ANGIOTENSIN PEC  | LEPTOR BLOCKERS   | Each of the preferred agents in the corresponding group must be   |
| BLOCKERS (ARBs)                       | AVAPRO (irbesartan)  | ATACAND (candesartan)   | tried for at least two weeks each before a non-preferred agent in that group will be authorized unless one of the exceptions on the   |
| Effective 4/2/07                      | BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan)   | TEVETEN (eprosartan)  | PA form is present.   |
|                                       |  | BINATIONS   |   |
|                                       | AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ) | ATACAND-HCT (candesartan/HCTZ) EXFORGE (valsartan/amlodipine) TEVETEN-HCT (eprosartan/HCTZ) |   |

#### **Version 2007.7**

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC<br>DRUG CLASS | PREFERRED<br>AGENTS    | NON-PREFERRED<br>AGENTS        | PA<br>CRITERIA  |
|---------------------------|------------------------|--------------------------------|---|
| ANGIOTENSIN MODULATORS    | ACE INF                | IIBITORS                       | Four of the preferred agents must be tried for at least 30 days   |
|                           | ALTACE (ramipril)      | ACEON (perindopril)            | each before a non-preferred agent will be authorized unless one   |
| Effective 10/01/07        | benazepril             | ACCUPRIL (quinapril)           | of the exceptions on the PA form is present.                      |
|                           | captopril              | CAPOTEN (captopril)            |   |
|                           | enalapril              | LOTENSIN (benazepril)          |   |
|                           | fosinopril             | MAVIK (trandolapril)           |   |
|                           | lisinopril             | moexepril                      |   |
|                           | quinapril              | MONOPRIL (fosinopril)          |   |
|                           |                        | PRINIVIL (lisinopril)          |   |
|                           |                        | trandolapril                   |   |
|                           |                        | UNIVASC (moexepril)            |   |
|                           |                        | VASOTEC (enalapril)            |   |
|                           |                        | ZESTRIL (lisinopril)           |   |
|                           | ACE INHIBITOR/DIUR     | ETIC COMBINATIONS              |   |
|                           | benazepril/HCTZ        | ACCURETIC (quinapril/HCTZ)     |   |
|                           | captopril/HCTZ         | CAPOZIDE (captopril/HCTZ)      |   |
|                           | enalapril/HCTZ         | LOTENSIN HCT (benazepril/HCTZ) |   |
|                           | fosinopril/HCTZ        | moexepril/HCTZ                 |   |
|                           | lisinopril/HCTZ        | MONOPRIL HCT (fosinopril/HCTZ) |   |
|                           | quinapril/HCTZ         | PRINZIDE (lisinopril/HCTZ)     |   |
|                           |                        | UNIRETIC (moexepril/HCTZ)      |   |
|                           |                        | VASERETIC (enalapril/HCTZ)     |   |
|                           |                        | ZESTORETIC (lisinopril/HCTZ)   |   |
|                           | DIRECT RENI            | N INHIBITORS                   |   |
|                           |                        | TEKTURNA (aliskerin)           |   |
| ANTICOAGULANTS,           | ARIXTRA (fondaparinux) | INNOHEP (tinzaparin)           | A trial of each of the preferred agents will be required before a |
| INJECTABLECL              | FRAGMIN (dalteparin)   |                                | non-preferred agent will be approved unless one of the            |
|                           | LOVENOX (enoxaparin)   |                                | exceptions on the PA form is present.                             |
| Effective 4/2/07          |                        |                                |   |
|                           |                        |                                |   |
|                           |                        |                                |   |
|                           |                        |                                |   |
|                           |                        |                                |   |
|                           |                        |                                |   |
|                           |                        |                                |   |

**Version 2007.7** 

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC      | PREFERRED                         | NON-PREFERRED               | PA  |
|------------------|-----------------------------------|-----------------------------|---|
| DRUG CLASS       | AGENTS                            | AGENTS                      | CRITERIA  |
| ANTICONVULSANTS  | BA                                | RBITURATES                  | Treatment naive patients must have a trial of a preferred agent   |
| ANTIGOTY GEGANTO | mephobarbital                     | MEBARAL (mephobarbital)     | before a non-preferred agent in its corresponding class will be   |
| Effective 4/2/07 | phenobarbital                     | MYSOLINE (primidone)        | authorized. Patients stabilized on non-preferred agents will  |
|                  | primidone                         | in recent (primaens)        | receive authorization to continue these drugs. Additions to that  |
|                  | •                                 | YDANTOINS                   | therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present. |
|                  | PEGANONE (ethotoin)               | DILANTIN (phenytoin)        | Lyrica requires a 30-day trial of gabapentin for treatment naïve patients.  |
|                  | phenytoin                         | EPITOL (phenytoin)          | patients.   |
|                  |                                   | PHENYTEK (phenytoin)        |   |
|                  | SL                                | JCCINIMIDES                 |   |
|                  | CELONTIN (methsuximide)           | ZARONTIN (ethosuximide)     |   |
|                  | ethosuximide                      |                             |   |
|                  | BEN                               | ZODIAZEPINES                |   |
|                  | clonazepam                        | KLONOPIN (clonazepam)       |   |
|                  | DIASTAT (diazepam rectal)         |                             |   |
|                  | diazepam                          |                             |   |
|                  | ADJUVANTS                         |                             |   |
|                  | carbamazepine                     | DEPAKENE (valproic acid)    |   |
|                  | CARBATROL (carbamazepine)         | NEURONTIN (gabapentin)      |   |
|                  | DEPAKOTE (divalproex)             | TEGRETOL (carbamazepine)    |   |
|                  | DEPAKOTE ER (divalproex)          | TEGRETOL XR (carbamazepine) |   |
|                  | DEPAKOTE SPRINKLE (divalproex)    | ZONEGRAN (zonisamide)       |   |
|                  | dilvalproex                       |                             |   |
|                  | EQUETRO (carbamazepine)           |                             |   |
|                  | FELBATOL (felbamate)              |                             |   |
|                  | gabapentin                        |                             |   |
|                  | GABITRIL (tiagabine)              |                             |   |
|                  | KEPPRA (levetiracetam)            |                             |   |
|                  | LAMICTAL (lamotrigine)            |                             |   |
|                  | LYRICA (pregabalin) <sup>CL</sup> |                             |   |
|                  | TOPAMAX (topiramate)              |                             |   |
|                  | TRILEPTAL (oxcarbazepine)         |                             |   |
|                  | valproic acid                     |                             |   |
|                  | zonisamide                        |                             |   |

**Version 2007.7** 

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC  | PREFERRED   | NON-PREFERRED   | PA   |
|--|---|---|--|
| DRUG CLASS   | AGENTS  | AGENTS  | CRITERIA   |
| ANTIDEPRESSANTS, OTHER (second generation, non-SSRI)  Effective 4/2/07 | bupropion SR CYMBALTA (duloxetine) EFFEXOR XR (venlafaxine) mirtazapine trazodone | bupropion IR bupropion XL DESYREL (trazodone) EFFEXOR (venlafaxine) EMSAM (selegiline) nefazodone   | A non-preferred agent will only be authorized if there has been a six-week trial of an SSRI and a preferred agent in this class unless one of the exceptions on the PA form is present.  Patients on a non-preferred agent will be authorized to continue on that agent. |
|  |   | REMERON (mirtazapine) venlafaxine WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion)                                    |  |
| ANTIDEPRESSANTS, SSRIS   | citalopram<br>fluoxetine  | CELEXA (citalopram) LEXAPRO (escitalopram)  | A trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the   |
| Effective 10/01/07   | fluvoxamine paroxetine sertraline   | PAXIL (paroxetine) PAXIL CR (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) RAPIFLUX (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline) | exceptions on the PA form is present.  Patients on a non-preferred agent will be authorized to continue on that agent.   |
| ANTIEMETICS, ORAL  |   | CANNABINOIDS  |  |
| Effective 10/01/07   |   | CESAMET (nabilone) MARINOL (dronabinol)   |  |
|  | 5HT3  | RECEPTOR BLOCKERS   | A trial of Zofran is required before a non-preferred agent will be   |
|  | ZOFRAN (ondansetron) ZOFRAN ODT (ondansetron)                                     | ANZEMET (dolasetron) KYTRIL (granisetron)   | authorized unless one of the exceptions on the PA form is present.   |
|  |   | ondansetron ondansetron ODT   | Quantity limits for Zofran - 14 tablets per 21 days; in cases of hyperemesis during pregnancy, increased quantities may be authorized.   |
|  | SUBST   | TANCE P ANTAGONISTS   | Quantity limits for Emend - 12 tablets per 28 days   |
|  | EMEND (aprepitant)  |   |  |

**Version 2007.7** 

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC          | PREFERRED                       | NON-PREFERRED                          | PA   |
|----------------------|---------------------------------|--|--|
| DRUG CLASS           | AGENTS                          | AGENTS                                 | CRITERIA   |
| ANTIFUNGALS, ORAL    | clotrimazole                    | ANCOBON (flucytosine)                  | Non-preferred agents will be approved only if one of the   |
|                      | fluconazole                     | DIFLUCAN (fluconazole)                 | exceptions on the PA form is present.  |
| Effective 10/01/07   | ketoconazole                    | GRIFULVIN V (griseofulvin)             |  |
|                      | MYCOSTATIN Pastilles (nystatin) | griseofulvin                           | PA is required when limits are exceeded.   |
|                      | nystatin                        | GRIS-PEG (griseofulvin)                |  |
|                      | terbinafine <sup>CL</sup>       | itraconazole                           | PA is not required for Grifulvin-V Suspension for children up to 6 years of age for the treatment of tinea capitis     |
|                      |                                 | LAMISIL (terbinafine) <sup>CL</sup>    | years or age for the treatment of threa capitis  |
|                      |                                 | MYCELEX (clotrimazole)                 |  |
|                      |                                 | MYCOSTATIN Tablets (nystatin)          |  |
|                      |                                 | NIZORAL (ketoconazole)                 |  |
|                      |                                 | NOXAFIL (posaconazole)                 |  |
|                      |                                 | SPORANOX (itraconazole)                |  |
|                      |                                 | VFEND (voriconazole)                   |  |
| ANTIFUNGALS, TOPICAL | ANTIFU                          | JNGALS                                 | Three of the preferred agents must be tried for at least two weeks   |
|                      | econazole                       | ciclopirox                             | each before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
| Effective 10/01/07   | ketoconazole                    | ERTACZO (sertaconazole)                | unless one of the exceptions on the FA form is present.  |
|                      | MENTAX (butenafine)             | EXELDERM (sulconazole)                 |  |
|                      | NAFTIN (naftifine)              | LOPROX (ciclopirox)                    |  |
|                      | nystatin                        | MYCOSTATIN (nystatin)                  |  |
|                      |                                 | NIZORAL (ketoconazole)                 |  |
|                      |                                 | OXISTAT (oxiconazole)                  |  |
|                      |                                 | PENLAC (ciclopirox)                    |  |
|                      |                                 | SPECTAZOLE (econazole)                 |  |
|                      |                                 | VUSION                                 |  |
|                      |                                 | (miconazole/petrolatum/zinc oxide)     |  |
|                      | ANTIFUNOAL OTER                 | XOLEGEL (ketoconazole)                 |  |
|                      |                                 | OID COMBINATIONS                       |  |
|                      | clotrimazole/betamethasone      | LOTRISONE (clotrimazole/betamethasone) |  |
|                      | nystatin/triamcinolone          | MYCOLOG (nystatin/triamcinolone)       |  |
|                      |                                 |  |  |
|                      |                                 |  |  |
|                      |                                 |  |  |
|                      |                                 |  |  |
|                      |                                 |  |  |
|                      |                                 |  |  |
|                      |                                 |  |  |

**Version 2007.7** 

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC               | PREFERRED                              | NON-PREFERRED                              | PA   |
|---------------------------|--|--|--|
| DRUG CLASS                | AGENTS                                 | AGENTS                                     | CRITERIA   |
| ANTIHISTAMINES, MINIMALLY | ANTIHISTAMINES                         |  | A preferred agent, in the age appropriate dosage form, must be   |
| SEDATING                  | ALAVERT (loratadine)                   | ALLEGRA (fexofenadine)                     | tried before a non-preferred agent will be authorized unless one                                       |
|                           | CLARINEX Syrup (desloratadine)         | CLARINEX Tablets (desloratadine)           | of the exceptions on the PA form is present.   |
| Effective 4/2/07          | Ioratadine                             | CLARITIN (loratadine)                      |  |
|                           | TAVIST-ND (loratadine)                 | fexofenadine                               |  |
|                           |  | ZYRTEC (cetirizine)                        |  |
|                           | ANTIHISTAMINE/DECONO                   | GESTANT COMBINATIONS                       |  |
|                           | ALAVERT-D (loratadine/pseudoephedrine) | ALLEGRA-D (fexofenadine/pseudoephedrine)   |  |
|                           | loratadine/pseudoephedrine             | CLARINEX-D (desloratadine/pseudoephedrine) |  |
|                           | SEMPREX-D                              | CLARITIN-D (loratadine/pseudoephedrine)    |  |
|                           | (acrivastine/ pseudoephedrine)         | ZYRTEC-D (cetirizine/pseudoephedrine)      |  |
| ANTIMIGRAINE AGENTS,      | AMERGE (naratriptan)                   | AXERT (almotriptan)                        | All of the preferred agents must be tried before a non-preferred                                       |
| TRIPTANS                  | IMITREX (sumatriptan)                  | FROVA (frovatriptan)                       | agent will be approved unless one of the exceptions on the PA  |
|                           | MAXALT (rizatriptan)                   | ZOMIG (zolmitriptan)                       | form is present.   |
| Effective 4/2/07          | RELPAX (eletriptan)                    |  |  |
|                           |  |  | Quantity limits apply for this drug class.   |
| ANTIPARKINSON'S AGENTS    |  | LINERGICS                                  | Patients starting therapy on drugs in this class must show a   |
| (Oral)                    | benztropine                            | COGENTIN (benztropine)                     | documented allergy to all of the preferred agents before a non-<br>preferred agent will be authorized. |
| F#= ative 40/04/07        | KEMADRIN (procyclidine)                |  | Patients on a non-preferred agent will be authorized to continue                                       |
| Effective 10/01/07        | trihexyphenidyl                        |  | on that agent.   |
|                           | COMT IN                                | HIBITORS                                   |  |
|                           |  | COMTAN (entacapone)                        |  |
|                           |  | TASMAR (tolcapone)                         |  |
|                           |  | AGONISTS                                   |  |
|                           | REQUIP (ropinirole)                    | MIRAPEX (pramipexole)                      |  |
|                           |  | KINSON'S AGENTS                            |  |
|                           | carbidopa/levodopa                     | AZILECT (rasagiline)                       |  |
|                           | selegiline                             | ELDEPRYL (selegiline)                      |  |
|                           | STALEVO (levodopa/                     | PARCOPA (levodopa/carbidopa)               |  |
|                           | carbidopa/entacapone)                  | SINEMET (levodopa/carbidopa)               |  |
|                           |  | ZELAPAR (selegiline)                       |  |
|                           |  |  |  |
|                           |  |  |  |
|                           |  |  |  |
|                           |  | T .  |  |

**Version 2007.7** 

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

|                           |                         | VEI SIOII 2001.1                | Originally Posted. 9/13/0   |
|---------------------------|-------------------------|---------------------------------|---|
| THERAPEUTIC<br>DRUG CLASS | PREFERRED<br>AGENTS     | NON-PREFERRED<br>AGENTS         | PA<br>CRITERIA  |
| ANTIPSYCHOTICS, ATYPICAL  |                         | ORAL                            | Upon discharge, hospitalized patients stabilized on non-preferred                               |
| (Oral)                    | clozapine               | ABILIFY (aripiprazole)          | agents will receive authorization to continue these drugs.                                      |
|                           | GEODON (ziprasidone)    | CLOZARIL (clozapine)            |   |
| Effective 10/01/07        | INVEGA (paliperidone)   | FAZACLO (clozapine)             | New patients for this class of drugs will be required to try a                                  |
|                           | RISPERDAL (risperidone) | SEROQUEL XR (quetiapine) NR     | preferred agent for two weeks unless one of the exceptions on the PA form is present.           |
|                           | SEROQUEL (quetiapine)   | ZYPREXA (olanzapine)            | the FA form is present.   |
|                           | ATYPICAL ANTIP          | SYCHOTIC/SSRI COMBINATIONS      |   |
|                           |                         | SYMBYAX (olanzapine/fluoxetine) |   |
| ANTIVIRALS                |                         | ANTI-HERPES                     | All of the appropriate preferred agents must be tried before the                                |
| (Oral)                    | acyclovir               | FAMVIR (famciclovir)            | non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
|                           | VALTREX (valacyclovir)  | ZOVIRAX (acyclovir)             | exceptions on the LA form is present.   |
| Effective 10/01/07        |                         | ANTI INFLUENZA                  | All of the appropriate preferred agents must be tried before the                                |
|                           | amantadine              | FLUMADINE (rimantadine)         | non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
|                           |                         | rimantadine                     | exceptions of the PA form is present.   |
|                           |                         | RELENZA (zanamivir)             |   |
|                           |                         | SYMMETREL (amantadine)          |   |
|                           |                         | TAMIFLU (oseltamivir)           |   |
| ATOPIC DERMATITIS         | ELIDEL (pimecrolimus)   |                                 |   |
| <b></b>                   | PROTOPIC (tacrolimus)   |                                 |   |
| Effective 10/01/07        |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |
|                           |                         |                                 |   |

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

#### **Version 2007.7**

| <b>-</b>                |  | version 2007.7                      | Originally Posted: 9/13/0  |
|-------------------------|--|-------------------------------------|--|
| THERAPEUTIC             | PREFERRED                              | NON-PREFERRED                       | PA   |
| DRUG CLASS              | AGENTS                                 | AGENTS                              | CRITERIA   |
| BETA BLOCKERS           | BETA BLOCKERS                          |                                     | If one of the exceptions on the PA form is present or if the   |
| (Oral)                  | acebutolol                             | BETAPACE (sotalol)                  | physician feels that the patient cannot be stabilized with any of<br>the preferred agents, one of the non-preferred agents will be |
|                         | atenolol                               | BLOCADREN (timolol)                 | approved.  |
| Effective 4/2/07        | betaxolol                              | CARTROL (carteolol)                 | аррточеа.  |
|                         | bisoprolol                             | CORGARD (nadolol)                   |  |
|                         | INDERAL LA (propranolol)               | INNOPRAN XL (propranolol)           |  |
|                         | metoprolol                             | KERLONE (betaxolol)                 |  |
|                         | nadolol                                | LEVATOL (penbutolol)                |  |
|                         | pindolol                               | LOPRESSOR (metoprolol)              |  |
|                         | propranolol                            | SECTRAL (acebutolol)                |  |
|                         | sotalol                                | TENORMIN (atenolol)                 |  |
|                         | timolol                                | ZEBETA (bisoprolol)                 |  |
|                         | TOPROL XL (metoprolol)                 |                                     |  |
|                         | BETA- AND ALPHA- BLOCKERS              |                                     |  |
|                         | COREG (carvedilol)                     | COREG CR (carvedilol) <sup>NR</sup> |  |
|                         | labetalol                              | TRANDATE (labetalol)                |  |
| BLADDER RELAXANT        | DITROPAN XL (oxybutynin)               | DETROL (tolterodine)                | All of the preferred agents in the class must be tried before a non-   |
| PREPARATIONS            | ENABLEX (darifenacin)                  | DETROL LA (tolterodine)             | preferred agent will be authorized unless one of the exceptions  |
|                         | oxybutynin                             | DITROPAN (oxybutynin)               | on the PA form is present.   |
| Effective 4/2/07        | oxybutynin ER                          |                                     |  |
|                         | OXYTROL (oxybutynin)                   |                                     |  |
|                         | SANCTURA (trospium)                    |                                     |  |
|                         | VESICARE (solifenacin)                 |                                     |  |
| BONE RESORPTION         |  | PHONATES                            | One of the preferred agents must be tried for at least one month   |
| SUPPRESSION AND RELATED | FOSAMAX (alendronate)                  | ACTONEL (risedronate)               | before a non-preferred agent will be authorized unless one of the  |
| AGENTS                  | FOSAMAX PLUS D (alendronate/vitamin D) | ACTONEL WITH CALCIUM                | exceptions on the PA form is present.  |
|                         | (4.0.1                                 | (risedronate/calcium)               |  |
| Effective 10/01/07      |  | BONIVA (ibandronate)                |  |
|                         |  | DIDRONEL (etidronate)               |  |
|                         | OTHER BONE RESORPTION SUP              | PRESSION AND RELATED AGENTS         |  |
|                         | MIACALCIN (calcitonin)                 | EVISTA (raloxifene)                 | 7  |
|                         | , , ,                                  | FORTEO (teriparatide)               |  |
|                         |  | FORTICAL (calcitonin)               |  |
|                         |  | ,                                   |  |
|                         |  |                                     |  |
|                         |  |                                     |  |

**Version 2007.7** 

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC<br>DRUG CLASS | PREFERRED<br>AGENTS               | NON-PREFERRED<br>AGENTS                    | PA<br>CRITERIA  |
|---------------------------|-----------------------------------|--|---|
| BPH AGENTS                | ALPHA B                           | LOCKERS                                    | One of the preferred agents must be tried before a non-preferred  |
|                           | doxazosin                         | CARDURA (doxazosin)                        | agent will be authorized unless one of the exceptions on the PA   |
| Effective 4/2/07          | FLOMAX (tamsulosin)               | CARDURA XL (doxazosin)                     | form is present.  |
|                           | terazosin                         | HYTRIN (terazosin)                         |   |
|                           | UROXATRAL (alfuzosin)             |  |   |
|                           | 5-ALPHA-REDUCTA                   | SE (5AR) INHIBITORS                        |   |
|                           | AVODART (dutasteride)             | finasteride                                |   |
|                           |                                   | PROSCAR (finasteride)                      |   |
| BRONCHODILATORS,          | ANTICHO                           | LINERGIC                                   | The preferred agents in the class must be tried before the non-   |
| ANTICHOLINERGIC           | ATROVENT HFA (ipratropium)        | ATROVENT Inhalation Solution (ipratropium) | preferred agent will be authorized unless one of the exceptions   |
|                           | ipratropium                       |  | on the PA form is present.  |
| Effective 10/01/07        | SPIRIVA (tiotropium)              |  | For coverely compressional notion to alloutered/investranium will be  |
|                           | ANTICHOLINERGIC-BETA              | AGONIST COMBINATIONS                       | For severely compromised patients, albuterol/ipratropium will be approved if the combined volume of albuterol and ipratropium |
|                           | COMBIVENT (albuterol/ipratropium) | albuterol/ipratropium                      | nebules is inhibitory.  |
|                           |                                   | DUONEB (albuterol/ipratropium)             |   |
| BRONCHODILATORS, BETA     | -,-                               | HORT-ACTING                                | All of the preferred agents in a group must be tried before a non-  |
| AGONIST                   | albuterol CFC                     | ALUPENT (metaproterenol)                   | preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.                      |
| F(C ): 40/04/07           | MAXAIR (pirbuterol)               | PROVENTIL (albuterol)                      | exceptions on the PA form is present.   |
| Effective 10/01/07        | PROAIR HFA (albuterol)            |  | Xopenex Inhalation Solution will be approved for 12 months for a  |
|                           | PROVENTIL HFA (albuterol)         |  | diagnosis of asthma or COPD for patients on concurrent asthma   |
|                           | VENTOLIN HFA (albuterol)          |  | controller therapy (either oral or inhaled) with documentation of   |
|                           | XOPENEX HFA (levalbuterol)        |  | failure on a trial of albuterol or documented intolerance of  |
|                           | ·                                 | ONG-ACTING                                 | albuterol, or for a concurrent diagnosis of heart disease.  |
|                           | FORADIL (formoterol)              | SEREVENT (salmeterol)                      | **NIP DA is required for ACCUNED for skildren on to Funder of   |
|                           | INHALATIO                         | N SOLUTION                                 | **No PA is required for ACCUNEB for children up to 5 years of age.  |
|                           | albuterol                         | ACCUNEB (albuterol)**                      | ugo.  |
|                           |                                   | BROVANA (arformoterol) <sup>NR</sup>       |   |
|                           |                                   | metaproterenol                             |   |
|                           |                                   | PROVENTIL (albuterol)                      |   |
|                           |                                   | XOPENEX (levalbuterol)                     |   |
|                           | -                                 | RAL  |   |
|                           | albuterol                         | BRETHINE (terbutaline)                     |   |
|                           | terbutaline                       | metaproterenol                             |   |
|                           |                                   | VOSPIRE ER (albuterol)                     |   |
|                           |                                   |  |   |
|                           |                                   |  |   |

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

#### **Version 2007.7**

|                          |                          | version 2007.7            | Originally Posted: 9/13/0  |
|--------------------------|--------------------------|---------------------------|--|
| THERAPEUTIC              | PREFERRED                | NON-PREFERRED             | PA   |
| DRUG CLASS               | AGENTS                   | AGENTS                    | CRITERIA   |
| CALCIUM CHANNEL BLOCKERS | SHORT-ACTING             |                           | One of the preferred agents must be tried before a non-preferred                 |
| (Oral)                   | diltiazem                | ADALAT (nifedipine)       | agent will be authorized unless one of the exceptions on the PA form is present. |
|                          | verapamil                | CALAN (verapamil)         | Torri is present.  |
| Effective 4/2/07         |                          | CARDENE (nicardipine)     | Nimediaine will be engroued with the engrousists diagnosis                       |
|                          |                          | CARDIZEM (diltiazem)      | Nimodipine will be approved with the appropriate diagnosis.                      |
|                          |                          | DYNACIRC (isradipine)     |  |
|                          |                          | isradipine                |  |
|                          |                          | nicardipine               |  |
|                          |                          | nifedipine                |  |
|                          |                          | NIMOTOP (nimodipine)      |  |
|                          |                          | PROCARDIA (nifedipine)    |  |
|                          | LO                       | ONG-ACTING                |  |
|                          | CARDIZEM LA (diltiazem)  | ADALAT CC (nifedipine)    |  |
|                          | diltiazem                | amlodipine                |  |
|                          | DYNACIRC CR (isradipine) | CALAN SR (verapamil)      |  |
|                          | felodipine               | CARDENE SR (nicardipine)  |  |
|                          | nifedipine               | CARDIZEM CD (diltiazem)   |  |
|                          | SULAR (nisoldipine)      | CARDIZEM SR (diltiazem)   |  |
|                          | verapamil                | COVERA-HS (verapamil)     |  |
|                          | VERELAN PM (verapamil)   | DILACOR XR (diltiazem)    |  |
|                          |                          | ISOPTIN SR (verapamil)    |  |
|                          |                          | NORVASC (amlodipine)      |  |
|                          |                          | PLENDIL (felodipine)      |  |
|                          |                          | PROCARDIA XL (nifedipine) |  |
|                          |                          | TIAZAC (diltiazem)        |  |
|                          |                          | VERELAN (verapamil)       |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |
|                          |                          |                           |  |

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

#### **Version 2007.7**

| THERAPEUTIC<br>DRUG CLASS                         | PREFERRED<br>AGENTS                               | NON-PREFERRED AGENTS  | PA<br>CRITERIA  |
|---|---|---|---|
| CEPHALOSPORINS AND                                | BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS |   | The preferred agents must be tried before a non-preferred agent   |
| RELATED ANTIBIOTICS (Oral)                        | amoxicillin/clavulanate                           | AUGMENTIN (amoxicillin/clavulanate) AUGMENTIN ES-600 (amoxicillin/clavulanate) AUGMENTIN XR (amoxicillin/clavulanate) | will be authorized unless one of the exceptions on the PA form is present.  |
| Effective 10/01/07                                | CEPHALO   | DSPORINS  |   |
|   | cefaclor  | CECLOR (cefaclor)   |   |
|   | cefadroxil  | CEDAX (ceftibuten)  |   |
|   | cefpodoxime                                       | cefdinir  |   |
|   | cefprozil   | CEFTIN (cefuroxime)   |   |
|   | cefuroxime  | CEFZIL (cefprozil)  |   |
|   | cephalexin  | DURICEF (cefadroxil)  |   |
|   | OMNICEF (cefdinir)                                | KEFLEX (cephalexin)   |   |
|   | SPECTRACEF (cefditoren)                           | PANIXINE (cephalexin)   |   |
|   |   | RANICLOR (cefaclor)   |   |
|   |   | SUPRAX (cefixime)   |   |
|   |   | VANTIN (cefpodoxime)  |   |
| CYTOKINE & CAM ANTAGONISTS                        | ENBREL (etanercept)                               |   |   |
|   | HUMIRA (adalimumab)                               |   |   |
| F# - + + - + 0 /04 /07                            | KINERET (anakinra)                                |   |   |
| Effective 10/01/07                                | RAPTIVA (efalizumab)                              |   |   |
| ERYTHROPOIESIS STIMULATING PROTEINS <sup>CL</sup> | ARANESP (darbepoetin)                             | EPOGEN (rHuEPO)   | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is |
| PROTEINS  | PROCRIT (rHuEPO)                                  |   | present.  |
| Effective 4/2/07                                  |   |   | F   |
| FLUROQUINOLONES, ORAL                             | AVELOX (moxifloxacin)                             | CIPRO (ciprofloxacin) Tablets   | One of the preferred agents must be tried before a non-preferred  |
| FLOROGOINOLONES, ORAL                             | CIPRO (ciprofloxacin) Suspension                  | CIPRO XR (ciprofloxacin)  | agent will be authorized unless one of the exceptions on the PA   |
| Effective 10/01/07                                | ciprofloxacin                                     | FACTIVE (gemifloxacin)  | form is present.  |
| Zinodave 10/01/01                                 | LEVAQUIN (levofloxacin)                           | FLOXIN (ofloxacin)  |   |
|   | ciprofloxacin ER                                  | ofloxacin   |   |
|   |   | NOROXIN (norfloxacin)   |   |
|   |   | PROQUIN XR (ciprofloxacin)  |   |
|   |   |   |   |
|   |   |   |   |
|   |   |   |   |
|   |   |   |   |
|   |   |   |   |

#### **Version 2007.7**

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC<br>DRUG CLASS                             | PREFERRED<br>AGENTS   | NON-PREFERRED<br>AGENTS   | PA<br>CRITERIA   |
|---|---|---|--|
| GLUCOCORTICOIDS, INHALED                              | GLUCOCORTICOIDS   |   | All of the preferred agents of a dosage form must be tried before  |
| Effective 10/01/07                                    | AEROBID (flunisolide) AEROBID-M (flunisolide) ASMANEX (mometasone) AZMACORT (triamcinolone) FLOVENT HFA (fluticasone) QVAR (beclomethasone) | PULMICORT (budesonide)  | a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present.  Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI. |
|   | GLUCOCORTICOID/BRONCH   | ODILATOR COMBINATIONS   |  |
|   | ADVAIR (fluticasone/salmeterol)  ADVAIR HFA  (fluticasone/salmeterol)   | SYMBICORT (budesonide/formoterol) <sup>NR</sup>                                       |  |
| GROWTH HORMONE <sup>CL</sup> Effective 4/2/07         | GENOTROPIN (somatropin) NUTROPIN AQ (somatropin) SAIZEN (somatropin)  | HUMATROPE (somatropin) NORDITROPIN (somatropin) NUTROPIN (somatropin)                 | The preferred agents, with the exception of Saizen, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.  |
|   | SEROSTIM (somatropin) TEV-TROPIN (somatropin)   | OMNITROPE (somatropin) NR ZORBTIVE (somatropin)                                       | Patients already on a non-preferred agent will receive authorization to continue therapy on that agent.  |
| HEPATITIS B TREATMENTS  Effective 10/01/07            | EPIVIR HBV (lamivudine) TYZEKA (telbivudine) HEPSERA (adefovir)   | BARACLUDE   | One of the preferred agents must be tried before the non-<br>preferred agent will be authorized unless one of the exceptions<br>on the PA form is present.   |
|   |   |   | Patients already on the non-preferred agent will receive authorization to continue therapy on that agent.  |
| HEPATITIS C TREATMENTS <sup>CL</sup> Effective 4/2/07 | PEGASYS (pegylated interferon) ribavirin  | COPEGUS (ribavirin) INFERGEN (consensus interferon) PEG-INTRON (pegylated interferon) | Patients already on a non-preferred interferon will receive authorization to continue therapy on that agent.   |
| Lifective 4/2/07                                      |   | REBETOL (ribavirin)   | Patients starting therapy in this class must try preferred agent of a dosage form before a non-preferred agent of that dosage form will be authorized.   |
| HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS            | BYETTA (exenatide)  JANUMET (sitagliptin/metformin)  JANUVIA (sitagliptin)  |   |  |
| Effective 10/01/07                                    | SYMLIN (amylin)   |   |  |
| HYPOGLYCEMICS, INSULINS                               | HUMALOG (insulin lispro) HUMALOG MIX (insulin lispro/lispro protamine)  | APIDRA (insulin glulisine)<br>EXUBERA (insulin)                                       | To receive authorization for Exubera, patients must meet the following criteria:  1. be 18 years or older;   |
| Effective 10/01/07                                    | HUMULIN (insulin) LANTUS (insulin glargine)   |   | 2. have no history of smoking in the past six months; 3. have no history of chronic lung disease in the past two   |

**Version 2007.7** 

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

|                             |                                       | VEISION ZUUT.I        | Originally Fosted. 9/13/07  |
|-----------------------------|---------------------------------------|-----------------------|---|
| THERAPEUTIC                 | PREFERRED                             | NON-PREFERRED         | PA  |
| DRUG CLASS                  | AGENTS                                | AGENTS                | CRITERIA  |
|                             | LEVEMIR (insulin detemir)             |                       | years or presence of acute lower respiratory lung   |
|                             | NOVOLIN (insulin)                     |                       | infection;  |
|                             | NOVOLOG (insulin aspart)              |                       | <ol> <li>have a base line spriometry to measure FEV1. For<br/>renewal, spriometry to measure FEV1 six months after</li> </ol>                                 |
|                             | NOVOLOG MIX                           |                       | treatment initiation and then annually from second  |
|                             | (insulin aspart/aspart protamine)     |                       | FEV1 measure;   |
|                             |                                       |                       | <ol> <li>have a diagnosis of Type 1 diabetes (stated or<br/>inferred) with concomitant use of a longer acting</li> </ol>                                      |
|                             |                                       |                       | insulin;<br>OR  |
|                             |                                       |                       | have a diagnosis of Type 2 diabetes (stated or  |
|                             |                                       |                       | inferred) and maximization of dosage of at least one  |
|                             |                                       |                       | available oral agent (sulfonylurea, metformin or thiazolindinediones), unless contraindicated;  |
|                             |                                       |                       | <ol> <li>have a diagnosis of lipodystrophy or needle phobia<br/>that prevents self-injection or injection by a caregiver.</li> </ol>                          |
|                             |                                       |                       | To receive authorization for Apidra, patients must meet the following criteria:   |
|                             |                                       |                       | 1. be 18 years or older;  |
|                             |                                       |                       | <ol><li>be currently on a regimen including a longer-acting or<br/>basal insulin.</li></ol>   |
|                             |                                       |                       | <ol> <li>have had a trial of a similar preferred agent, Novolog<br/>or Humulin, with documentation that the desired<br/>results were not achieved.</li> </ol> |
| HYPOGLYCEMICS, MEGLITINIDES | STARLIX (nateglinide)                 | PRANDIN (repaglinide) | The preferred agent must be tried before a non-preferred agent  |
|                             |                                       |                       | will be authorized, unless one of the exceptions on the PA form is present.   |
| Effective 4/2/07            |                                       |                       | is present.   |
| HYPOGLYCEMICS, TZDS         | THIAZOLINEDIONES                      |                       |   |
|                             | ACTOS (pioglitazone)                  |                       |   |
| Effective 4/2/07            | AVANDIA (rosiglitazone)               |                       |   |
|                             |                                       | BINATIONS             |   |
|                             | ACTOPLUS MET (pioglitazone/metformin) |                       |   |
|                             | AVANDAMET (rosiglitazone/metformin)   |                       |   |
|                             | AVANDARYL (rosiglitazone/glimepiride) |                       |   |
|                             | DUETACT (pioglitazone/glimepiride)    |                       |   |
|                             |                                       |                       |   |
|                             |                                       |                       |   |
|                             |                                       |                       |   |

**Version 2007.7** 

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

| THERAPEUTIC DRUG CLASS     | PREFERRED<br>AGENTS  | NON-PREFERRED<br>AGENTS                      | PA<br>CRITERIA  |
|----------------------------|--|--|---|
| INTRANASAL RHINITIS AGENTS | ANTICHOLINERGICS   |  | All of the preferred agents must be tried before a non-preferred  |
| Effective 10/01/07         |  | ATROVENT (ipratropium) ipratropium           | agent will be authorized unless one of the exceptions on the PA form is present.  |
|                            | ANTIHIST   |  |   |
|                            | ASTELIN (azelastine)   |  | 1   |
|                            | CORTICOS   | TEROIDS                                      | 1   |
|                            | FLONASE (fluticasone propionate)   | BECONASE AQ (beclomethasone)                 | ]   |
|                            | NASACORT AQ (triamcinolone)  | flunisolide                                  |   |
|                            | NASONEX (mometasone)   | fluticasone propionate                       |   |
|                            |  | NASALIDE (flunisolide)                       |   |
|                            |  | NASAREL (flunisolide)                        |   |
|                            |  | RHINOCORT AQUA (budesonide)                  |   |
|                            |  | VERAMYST (fluticasone furoate) <sup>NR</sup> |   |
| LEUKOTRIENE MODIFIERS      | ACCOLATE (zafirlukast)   | ZYFLO (zileuton)                             |   |
|                            | SINGULAIR (montelukast)  |  |   |
| Effective 10/01/07         |  |  |   |
| LIPOTROPICS, OTHER         | BILE ACID SEQUESTRANTS   |  | The preferred agents must be tried before a non-preferred agent   |
| (non-statins)              | cholestyramine   | COLESTID (colestipol)                        | will be authorized unless one of the exceptions on the PA form  |
|                            | colestipol   | QUESTRAN (cholestyramine)                    | present.  |
| Effective 4/2/07           |  | WELCHOL (colesevalam)                        | Zetia, as monotherapy, will only be approved for patients who   |
|                            | CHOLESTEROL ABSORPTION INHIBITORS  |  | cannot take statins or other preferred agents.  |
|                            |  | ZETIA (ezetimibe)                            | , °   |
|                            | FATTY A  | 1  | Zetia and Welchol will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a      |
|                            |  | OMACOR                                       |   |
|                            | FIRRIO AGID D  | (omega-3-acid ethyl esters)                  | statin after 12 weeks of therapy.   |
|                            | FIBRIC ACID D  |  | If a stigate we will also addition of Zatio to Zacou to calcious and  |
|                            | fenofibrate  | ANTARA (fenofibrate)                         | If patients require the addition of Zetia to Zocor to achieve goal, use of the combination product, Vytorin, will be required. If |
|                            | gemfibrozil TDICOR (fanafibrata)   | LOFIBRA (fenofibrate)                        | patients are on other statins and require the addition of Zetia,  |
|                            | TRICOR (fenofibrate)   | LOPID (gemfibrozil) TRIGLIDE (fenofibrate)   | patients will not be required to switch the statin that they have   |
|                            | NIACIN   |  | been using.   |
|                            | niacin   | NIACELS (niacin)                             | †   |
|                            | NIASPAN (niacin)   | NIADELAY (niacin)                            |   |
|                            | The second of th | SLO-NIACIN (niacin)                          |   |
|                            |  |  |   |
|                            |  |  |   |

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

#### **Version 2007.7**

| THERABELITIO                            | 2255222                         | VCISION ZOUT.I                       | Originally 1 Osted: 3/13/01   |
|---|---------------------------------|--------------------------------------|---|
| THERAPEUTIC                             | PREFERRED<br>AGENTS             | NON-PREFERRED<br>AGENTS              | PA  |
| DRUG CLASS                              | AGENTS                          |                                      | CRITERIA  |
| LIPOTROPICS, STATINS                    | STATINS                         |                                      | One of the preferred statins must be tried before a non-preferred   |
|   | ALTOPREV (lovastatin)           | MEVACOR (lovastatin)                 | agent will be authorized unless one of the exceptions on the PA     |
| Effective 4/2/07                        | CRESTOR (rosuvastatin)          | PRAVACHOL (pravastatin)              | form is present.  |
|   | LESCOL (fluvastatin)            | pravastatin                          |   |
|   | LESCOL XL (fluvastatin)         | ZOCOR (simvastatin)                  |   |
|   | LIPITOR (atorvastatin)          |                                      |   |
|   | lovastatin                      |                                      |   |
|   | simvastatin                     |                                      |   |
|   | STATIN                          | N COMBINATIONS                       |   |
|   | ADVICOR (lovastatin/niacin)     | CADUET (atorvastatin/amlodipine)     |   |
|   | VYTORIN (ezetimibe/simvastatin) |                                      |   |
| MACROLIDES/KETOLIDES                    | M                               | IACROLIDES                           | The preferred agents must be tried before a non-preferred agent     |
| (Oral)                                  | azithromycin                    | BIAXIN (clarithromycin)              | will be authorized unless one of the exceptions on the PA form is   |
|   | clarithromycin                  | BIAXIN XL (clarithromycin)           | present.  |
| Effective 10/01/07                      | erythromycin                    | E.E.S. (erythromycin ethylsuccinate) |   |
|   |                                 | E-MYCIN (erythromycin)               |   |
|   |                                 | ERYC (erythromycin)                  |   |
|   |                                 | ERYPED (erythromycin ethylsuccinate) |   |
|   |                                 | ERY-TAB (erythromycin)               |   |
|   |                                 | ERYTHROCIN (erythromycin stearate)   |   |
|   |                                 | erythromycin estolate                |   |
|   |                                 | PCE (erythromycin)                   |   |
|   |                                 | ZITHROMAX (azithromycin)             |   |
|   |                                 | ZMAX (azithromycin)                  |   |
|   | KETOLIDES                       |                                      | Requests for telithromycin will be authorized if there is           |
|   |                                 | KETEK (telithromycin)                | documentation of the use of any antibiotic within the past 28 days. |
| MULTIPLE SCLEROSIS AGENTS <sup>CL</sup> | AVONEX (interferon beta-1a)     |                                      |   |
|   | BETASERON (interferon beta-1b)  |                                      |   |
| Effective 4/2/07                        | COPAXONE (glatiramer)           |                                      |   |
|   | REBIF (interferon beta-1a)      |                                      |   |

REVISED 9/18/07 Implementation Date: 10/01/07 Originally Posted: 9/13/07

#### **Version 2007.7**

|                    |                        | 70101011 200111                    | Originally Foctor. Of 16/61                                       |
|--------------------|------------------------|------------------------------------|---|
| THERAPEUTIC        | PREFERRED              | NON-PREFERRED                      | PA  |
| DRUG CLASS         | AGENTS                 | AGENTS                             | CRITERIA  |
| NSAIDS             |                        | NONSELECTIVE                       | The preferred agents must be tried before a non-preferred agent   |
|                    | diclofenac             | ADVIL (ibuprofen)                  | will be authorized unless one of the exceptions on the PA form is |
| Effective 10/01/07 | etodolac               | ANAPROX (naproxen)                 | present.  |
|                    | fenoprofen             | ANSAID (flurbiprofen)              |   |
|                    | flurbiprofen           | CATAFLAM (diclofenac)              |   |
|                    | ibuprofen (Rx and OTC) | CLINORIL (sulindac)                |   |
|                    | indomethacin           | DAYPRO (oxaprozin)                 |   |
|                    | ketorolac              | FELDENE (piroxicam)                |   |
|                    | naproxen (Rx only)     | INDOCIN (indomethacin)             |   |
|                    | oxaprozin              | ketoprofen                         |   |
|                    | piroxicam              | LODINE (etodolac)                  |   |
|                    | sulindac               | meclofenamate                      |   |
|                    |                        | mefenamic acid                     |   |
|                    |                        | MOTRIN (ibuprofen)                 |   |
|                    |                        | nabumetone                         |   |
|                    |                        | NALFON (fenoprofen)                |   |
|                    |                        | NAPRELAN (naproxen)                |   |
|                    |                        | NAPROSYN (naproxen)                |   |
|                    |                        | NUPRIN (ibuprofen)                 |   |
|                    |                        | ORUDIS (ketoprofen)                |   |
|                    |                        | PONSTEL (meclofenamate)            |   |
|                    |                        | tolmetin                           |   |
|                    |                        | VOLTAREN (diclofenac)              |   |
|                    | NSAID/GI P             | ROTECTANT COMBINATIONS             |   |
|                    |                        | ARTHROTEC (diclofenac/misoprostol) |   |
|                    |                        | PREVACID NAPRAPAC                  |   |
|                    |                        | (naproxen/lansoprazole)            |   |
|                    |                        | COX-II SELECTIVE <sup>CL</sup>     | COX-II selective NSAIDs will be approved for patients with a GI   |
|                    |                        | CELEBREX (celecoxib)               | Risk Score of ≥13.  |
|                    |                        | meloxicam                          |   |
|                    |                        | MOBIC (meloxicam)                  |   |
| OPHTHALMIC         | ciprofloxacin          | CILOXAN (ciprofloxacin)            | All of the preferred agents must be tried before non-preferred    |
| FLUOROQUINOLONES   | ofloxacin              | OCUFLOX (ofloxacin)                | agents will be authorized unless one of the exceptions on the PA  |
|                    | VIGAMOX (moxifloxacin) | QUIXIN (levofloxacin)              | form is present.  |
| Effective 10/01/07 | ,                      | ZYMAR (gatifloxacin)               |   |

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

**Version 2007.7** 

| Version 2007.7 Originally Posted.  | 3/13/01     |
|--|-------------|
| THERAPEUTIC PREFERRED NON-PREFERRED PA   |             |
| DRUG CLASS AGENTS AGENTS CRITERIA  |             |
| PHTHALMICS FOR ALLERGIC ACULAR (ketorolac) ALOCRIL (nedocromil) All of the preferred agents must be tried before not   |             |
| ONJUNCTIVITIS  ALAWAY (ketotifen)  ALAMAST (pemirolast)  ALAWAY (ketotifen)  ALAWAST (pemirolast)  | ons on the  |
| ALREX (loteprednol)  ALOMIDE (lodoxamide)  PA form is present.   |             |
| ffective 10/01/07 cromolyn CROLOM (cromolyn)   |             |
| ELESTAT (epinastine) EMADINE (emedastine)  |             |
| OPTIVAR (azelastine) ketotifen   |             |
| PATADAY (olopatadine) OPTICROM (cromolyn)  |             |
| PATANOL (olopatadine)  |             |
| ZADITOR OTC (ketotifen)  |             |
| PHTHALMICS, GLAUCOMA PARASYMPATHOMIMETICS Authorization for a non-preferred agent will only be given by the control of the con | en if there |
| GENTS CARBOPTIC (carbachol) ISOPTO CARPINE (pilocarpine) is an allergy to the preferred agents.  |             |
| ISOPTO CARBACHOL (carbachol) PILOPINE HS (pilocarpine)   |             |
| ffective 10/01/07 PHOSPHOLINE IODIDE (echothiophate iodide)  |             |
| pilocarpine  |             |
| SYMPATHOMIMETICS   |             |
| ALPHAGAN P (brimonidine) ALPHAGAN (brimonidine)  |             |
| brimonidine PROPINE (dipivefrin)   |             |
| dipivefrin   |             |
| BETA BLOCKERS  |             |
| BETIMOL (timolol) BETAGAN (levobunolol)  |             |
| BETOPTIC S (betaxolol) OPTIPRANOLOL (metipranolol)   |             |
| betaxolol TIMOPTIC (timolol)   |             |
| carteolol  |             |
| ISTALOL (timolol)  |             |
| levobunolol  |             |
| metipranolol   |             |
| timolol  |             |
| CARBONIC ANHYDRASE INHIBITORS  |             |
| AZOPT (brinzolamide)   |             |
| TRUSOPT (dorzolamide)  |             |
| PROSTAGLANDIN ANALOGS  |             |
| LUMIGAN (bimatoprost) XALATAN (latanoprost)  |             |
| TRAVATAN (travoprost)  |             |
| TRAVATAN-Z (travaprost)  |             |
| COMBINATION AGENTS   |             |
| COMBINATION AGENTS   |             |

**REVISED 9/18/07** Implementation Date: 10/01/07 Originally Posted: 9/13/07

#### **Version 2007.7**

|   | 10.0.0.1 2007.17  | Griginary roctou. Grigor   |
|---|---|--|
| PREFERRED   | NON-PREFERRED   | PA   |
| AGENTS  | AGENTS  | CRITERIA   |
| flurbiprofen ACULAR LS (ketorolac) ACULAR PF (ketorolac) XIBROM (bromfenac) NEVANAC (nepafenac) | diclofenac  | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.  |
| CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin)                                       | CIPRO HC (ciprofloxacin/hydrocortisone)   | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.  |
| FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer)                               |   |  |
| AGGRENOX (dipyridamole/ASA) PLAVIX (clopidogrel)  | dipyridamole PERSANTINE (dipyridamole) TICLID (ticlopidine) ticlopidine   | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.  |
| NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole)  | ACIPHEX (rabeprazole) omeprazole PREVACID Solu-Tabs (lansoprazole) PREVACID Suspension (lansoprazole) PRILOSEC (omeprazole) PROTONIX (pantoprazole) ZEGERID (omeprazole/sodium bicarbonate)   | The preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.  Prior authorization is not required for Prevacid Solu-Tabs for patients ≤8 years of age.   |
| BENZODIAZEPINES   |   | The preferred agent must be tried for 14 days before a non-  |
| temazepam   | DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) PROSOM (estazolam) RESTORIL (temazepam) Triazolam  | preferred agent will be authorized unless one of the exceptions on the PA form is present.   |
|   | flurbiprofen ACULAR LS (ketorolac) ACULAR PF (ketorolac) XIBROM (bromfenac) NEVANAC (nepafenac) CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin)  FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer) AGGRENOX (dipyridamole/ASA) PLAVIX (clopidogrel)  NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole) | flurbiprofen ACULAR LS (ketorolac) ACULAR PF (ketorolac) XIBROM (bromfenac) NEVANAC (nepafenac)  CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin)  FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer)  AGGRENOX (dipyridamole/ASA) PLAVIX (clopidogrel)  NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole) PREVACID Sulus-Tabs (lansoprazole) PRE |

**Version 2007.7** Originally Posted: 9/13/07 **NON-PREFERRED THERAPEUTIC PREFERRED** PΑ **AGENTS AGENTS DRUG CLASS CRITERIA OTHERS** AMBIEN (zolpidem) zolpidem AMBIEN CR (zolpidem) AQUA CHLORAL (chloral hydrate) chloral hydrate LUNESTA (eszopiclone) ROZEREM (ramelteon) SOMNOTE (chloral hydrate) SONATA (zaleplon) **AMPHETAMINES** STIMULANTS AND RELATED Except for Strattera, PA is required for adults >18 years. **AGENTS** ADDERALL XR **ADDERALL** (amphetamine salt combination) (amphetamine salt combination) One of the preferred agents in each group (amphetamines and Effective 10/01/07 non-amphetamines) must be tried before a non-preferred agent amphetamine salt combination DESOXYN (methamphetamine) will be authorized. dextroamphetamine DEXTROSTAT (dextroamphetamine) VYVANCE (lisdexamphetamine) NR Amphetamines will be authorized for the treatment of depression **NON-AMPHETAMINE** only after documented failure of multiple antidepressants. CONCERTA (methylphenidate) dexmethylphenidate DAYTRANA (methylphenidate) METADATE ER (methylphenidate) Provigil will only be approved for patients >16 years of age with FOCALIN (dexmethylphenidate) PROVIGIL (modafanil) a diagnosis of narcolepsy. FOCALIN XR (dexmethylphenidate) RITALIN (methylphenidate) METADATE CD (methylphenidate) RITALIN LA (methylphenidate) Straterra will not be approved for concurrent administration with methylphenidate RITALIN-SR (methylphenidate) amphetamines or methyphenidates, exept for 30 days or less for tapering purposes. Only two doses of each strength, or two methylphenidate ER concurrent doses of any strength, and a maximum of one dose STRATTERA (atomoxetine) of a 60 mg capsule, will be approved in a 34-day period. **ULCERATIVE COLITIS AGENTS** The preferred agents of a dosage form must be tried before a **ORAL** non-preferred agent of that dosage form will be authorized AZULFIDINE (sulfasalazine) ASACOL (mesalamine) unless one of the exceptions on the PA form is present. Fffective 4/2/07 COLAZAL (balsalazide) LIALDA (mesalamine)<sup>NR</sup> DIPENTUM (olsalazine) PENTASA (mesalamine) sulfasalazine **RECTAL** ROWASA (mesalamine) CANASA (mesalamine) mesalamine

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

**REVISED 9/18/07** 

Implementation Date: 10/01/07

CL - Requires Clinical PA

NR – New drug has not been reviewed by P & T Committee